標題羅格列酮

Rosiglitazone is a member of the thiazolidinedione family. It effectively lowers glucose levels by enhancing the response of target cells to insulin, without causing increased stimulation ａnd release of insulin by the pancreatic beta cells. Rosiglitazone functions by activating the nuclear peroxisome proliferator-activated (PPAR) receptor gamma, which plays a key role in regulating adipogenesis, glucose metabolism, ａnd genetic networks. It exhibits high potency as a thiazolidinedione, with a binding affinity for PPAR-gamma that is 30-fold higher than pioglitazone. Furthermore, it increases insulin-stimulated IRS-1/2 in skeletal muscle ａnd adipose tissue, leading to the expression of the GLUT4 glucose transporter.[1]

羅格列酮已被用于：

• 脂肪細胞分化的培養基成分[2]
• 人結腸癌細胞的細胞增殖測定[3]
• 脂肪細胞中Bcl-2樣蛋白13（Bcl2113）的表達[4]
• 作為過氧化物酶體增殖物激活受體γ（PPARγ）的配體[5]

羅格列酮是PPARγ的強效激動劑，對人受體的EC50為43 nM。 它是一種抗糖尿病藥，作為胰島素增敏劑，可與脂肪細胞的PPARγ受體結合并使細胞對胰島素更敏感。

《受體分類和信號轉導》手冊的 AMPK 和 核受體（PPAR） 頁面有該化合物的介紹。想要瀏覽手冊的其他頁面， 請單擊此處。

該化合物是ADME Tox和基因調控研究的特色產品。發現更多 ADME Tox 和 基因調控 特色產品。想要了解有關生物活性小分子在其他研究域應用的更多信息，請訪問 sigma.com/discover-bsm。

該化合物由 GlaxoSmithKline開發。想要瀏覽其他由制藥公司開發的化合物以及已批準物/候選藥物清單， 請單擊此處。